Kihealth is developing a blood test that utilizes PCR-based molecular diagnostics to identify metabolic risk factors for diabetes before symptoms appear. This proactive approach enables individuals to gain critical insights into their health, allowing for early intervention and disease prevention.
Funding
Funding not disclosed
Founders
Product
Problem
A significant portion of the adult population is at high risk of developing metabolic disorders like diabetes, heart disease, and autoimmune disorders. Early detection of metabolic risk factors is crucial for preventing disease onset, but traditional methods often lack the sensitivity and accessibility needed for proactive intervention.
Solution
Kihealth offers a suite of preventative diagnostic tests that utilize PCR-based molecular diagnostics to identify metabolic risk factors before symptoms appear. These at-home tests analyze crucial biomarkers, providing individuals with actionable insights into their metabolic health and potential disease risks. By determining the root cause of diseases at an early stage, Kihealth empowers individuals to take proactive steps toward a healthier well-being and prevent disease onset. The company's pioneering diagnostic portfolio goes beyond simple health checks, offering a direct path to optimal well-being and longevity.
Target Audience
The primary target audience is adults at high risk of developing metabolic disorders, such as diabetes, heart disease, and autoimmune disorders, who are seeking proactive health insights and early disease prevention strategies.
Features
- At-home sample collection for convenient and accessible testing.
- PCR-based molecular diagnostics for sensitive and accurate biomarker analysis.
- Comprehensive analysis of key biomarkers related to metabolic health and disease risk.
- Actionable insights and personalized recommendations based on test results.
- Focus on early detection and prevention of metabolic disorders.